A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Stopped early · Phase 4

Conditions studied: Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder

In brief

The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls. In addition, secondary and exploratory objectives were to assess medication adherence, healthcare utilization and costs, and patient-reported outcomes.

Key facts

Study ID
NCT03643159
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
People needed
2
Starts
2018-06-28
Expected to finish
2018-10-17
Last updated by the study team
2019-11-08

Who can join

Age: 18 and older, up to 63. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.